234 related articles for article (PubMed ID: 25029934)
21. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
22. PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
Shamim SA; Kumar A; Kumar R
PET Clin; 2015 Jul; 10(3):411-21. PubMed ID: 26099675
[TBL] [Abstract][Full Text] [Related]
23. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
24. [Contributions of nuclear medicine to the diagnosis and follow-up of gastroenteropancreatic neuroendocrine tumors].
Casanovas MM
Endocrinol Nutr; 2009 Sep; 56 Suppl 3():14-9. PubMed ID: 20542215
[TBL] [Abstract][Full Text] [Related]
25. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
26. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.
Kjaer A; Knigge U
Scand J Gastroenterol; 2015 Jun; 50(6):740-7. PubMed ID: 25959100
[TBL] [Abstract][Full Text] [Related]
27. Preclinical studies of SPECT and PET tracers for NET.
Brom M; Boerman O; Gotthardt M; Oyen WJ
PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
[TBL] [Abstract][Full Text] [Related]
28. Role of PET/CT in the functional imaging of endocrine pancreatic tumors.
Rufini V; Baum RP; Castaldi P; Treglia G; De Gaetano AM; Carreras C; Kaemmerer D; Hommann M; Hörsch D; Bonomo L; Giordano A
Abdom Imaging; 2012 Dec; 37(6):1004-20. PubMed ID: 22422069
[TBL] [Abstract][Full Text] [Related]
29. Can PET/CT guide the personalized treatment of patients with gastroenteropancreatic neuroendocrine neoplasms?
Schillaci O
J Nucl Med; 2014 Nov; 55(11):1757-8. PubMed ID: 25342386
[No Abstract] [Full Text] [Related]
30. Molecular imaging of gastroenteropancreatic neuroendocrine tumors.
Miederer M; Weber MM; Fottner C
Gastroenterol Clin North Am; 2010 Dec; 39(4):923-35. PubMed ID: 21093764
[TBL] [Abstract][Full Text] [Related]
31. Developments in PET for the detection of endocrine tumours.
Eriksson B; Orlefors H; Oberg K; Sundin A; Bergström M; Långström B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):311-24. PubMed ID: 15763703
[TBL] [Abstract][Full Text] [Related]
32. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1.
van Asselt SJ; Brouwers AH; van Dullemen HM; van der Jagt EJ; Bongaerts AH; Kema IP; Koopmans KP; Valk GD; Timmers HJ; de Herder WW; Feelders RA; Fockens P; Sluiter WJ; de Vries EG; Links TP
Gastrointest Endosc; 2015 Jan; 81(1):159-167.e2. PubMed ID: 25527055
[TBL] [Abstract][Full Text] [Related]
33. Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions.
Deroose CM; Hindié E; Kebebew E; Goichot B; Pacak K; Taïeb D; Imperiale A
J Nucl Med; 2016 Dec; 57(12):1949-1956. PubMed ID: 27811124
[TBL] [Abstract][Full Text] [Related]
34. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
Adkins J; Lu Y
Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
[TBL] [Abstract][Full Text] [Related]
35. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
36. [Positron emission tomography with fluorodeoxyglucose in gastro-entero-pancreatic tumors: diagnostic role and prognostic implications].
Pasquali C; Sperti C; Lunardi C; Scappin S; Chierichetti F; Liessi G; Pedrazzoli S
Suppl Tumori; 2005; 4(3):S68-71. PubMed ID: 16437910
[TBL] [Abstract][Full Text] [Related]
37. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
38. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
[TBL] [Abstract][Full Text] [Related]
39. PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors.
Pinho DF; Subramaniam RM
PET Clin; 2017 Oct; 12(4):407-421. PubMed ID: 28867112
[No Abstract] [Full Text] [Related]
40. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
